Treatment of Sepsis with Talactoferrin
Department of Health and Human Services
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Socially and Economically Disadvantaged:
AbstractDESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succumbing to the disease process at an average cost of 22,000 per patient. Successful development of TLF-based thera py for sepsis would satisfy a significant unmet medical need. Agennix has now established a manufacture of a pharmaceutical-grade talactoferrin, it has demonstrated its safety in clinical studies for various indications, and is now interacting with the FDA to obtain a go-ahead to initiate clinical Phase 3 studies in cancer. The development of talactoferrin is therefore at a stage that a demonstration of its clinical efficacy in sepsis would put the generation of a product to treat sepsis on a relatively eas y and straightforward path.
* information listed above is at the time of submission.